Jefferies analyst David Windley raised the firm’s price target on Humana (HUM) to $586 from $580 and keeps a Buy rating on the shares. The firm is tweaking its estimates and targets for Humana, UnitedHealth (UNH) and Centene (CNC) after having analyzed which MCOs will capitalize on community MA retrenchment in 2024. The firm calculates the opportunity is 1%-3% of Humana’s 2024 EPS, while the opportunity for UnitedHealth is only 0.5% of 2024 EPS, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Humana, Denver Health enter agreement for Medicare Advantage members
- GoodRx deals may add pressure for pacts on other large PBMs, says TD Cowen
- Humana reaffirms FY23 view of at least $28.25 in adjusted EPS, consensus $28.29
- Humana sues U.S. government to block Medicare audit rule
- Humana sues U.S. to block Medicare audit rule, Bloomberg reports